Aurinia starts PRESERVE trial combining LUPKYNIS with biologics in lupus nephritis

Aurinia Pharmaceuticals disclosed in an August 6, 2026 earnings release that it has recently initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis.¹ The study will investigate whether the multi-target approach of combining LUPKYNIS with these biologic agents improves outcomes in patients with lupus nephritis.¹

Enrollment is set at approximately 150 patients across approximately 50 sites in the US.¹ The primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months.¹

Aurinia also said it has now initiated clinical development of aritinercept in four potential indications.¹ Aritinercept is described as a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.¹

On financials, the company reported total revenue for the three and six months ended June 30, 2026 of $83.2 million and $160.9 million, up 19% and 21% respectively from $70.0 million and $132.5 million in the same periods of 2025.¹ Net product sales of LUPKYNIS were $79.4 million and $153.0 million for the quarter and half year, up 19% and 21% respectively.¹

As of June 30, 2026, the company held cash, cash equivalents, restricted cash and investments of $443.1 million, compared to $398.0 million at December 31, 2025.¹ Aurinia reiterated its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025.¹